Advances in the Study of Aerobic Glycolytic Effects in Resistance to Radiotherapy in Malignant Tumors

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2023 Feb 22

PMID 36811010

Authors

Yuyi Liu

Zhengfu Feng

Pingmei Zhang

Honghao Chen

Song Zhu

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Aerobic glycolysis is a metabolic mode of tumor cells different from normal cells that plays an important role in tumor proliferation and distant metastasis. Radiotherapy has now become a routine and effective treatment for many malignancies, however, resistance to radiotherapy remains a major challenge in the treatment of malignant tumors. Recent studies have found that the abnormal activity of the aerobic glycolysis process in tumor cells is most likely involved in regulating chemoresistance and radiation therapy resistance in malignant tumors. However, research on the functions and mechanisms of aerobic glycolysis in the molecular mechanisms of resistance to radiotherapy in malignant tumors is still in its early stages. This review collects recent studies on the effects of aerobic glycolysis and radiation therapy resistance in malignant tumors, to further understand the progress in this area. This research may more effectively guide the clinical development of more powerful treatment plans for radiation therapy resistant subtypes of cancer patients, and take an important step to improve the disease control rate of radiation therapy resistant subtypes of cancer patients.

References

Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q . Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 2008; 7(7):2192-202. PMC: 2515935. DOI: 10.1158/1535-7163.MCT-08-0333. View

Corbet C, Bastien E, Draoui N, Doix B, Mignion L, Jordan B . Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018; 9(1):1208. PMC: 5865202. DOI: 10.1038/s41467-018-03525-0. View

Payen V, Mina E, Van Hee V, Porporato P, Sonveaux P . Monocarboxylate transporters in cancer. Mol Metab. 2019; 33:48-66. PMC: 7056923. DOI: 10.1016/j.molmet.2019.07.006. View

Liu G, Kelly W, Wilding G, Leopold L, Brill K, Somer B . An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009; 15(9):3172-6. PMC: 2921915. DOI: 10.1158/1078-0432.CCR-08-2985. View

Fisel P, Schaeffeler E, Schwab M . Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018; 11(4):352-364. PMC: 6039204. DOI: 10.1111/cts.12551. View

Martinez-Outschoorn U, Lisanti M, Sotgia F . Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014; 25:47-60. DOI: 10.1016/j.semcancer.2014.01.005. View

Halestrap A, Wilson M . The monocarboxylate transporter family--role and regulation. IUBMB Life. 2011; 64(2):109-19. DOI: 10.1002/iub.572. View

Le A, Cooper C, Gouw A, Dinavahi R, Maitra A, Deck L . Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010; 107(5):2037-42. PMC: 2836706. DOI: 10.1073/pnas.0914433107. View

Doherty J, Cleveland J . Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123(9):3685-92. PMC: 3754272. DOI: 10.1172/JCI69741. View

10.

Koukourakis M, Giatromanolaki A, Harris A, Sivridis E . Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006; 66(2):632-7. DOI: 10.1158/0008-5472.CAN-05-3260. View

11.

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

12.

Navale A, Paranjape A . Glucose transporters: physiological and pathological roles. Biophys Rev. 2017; 8(1):5-9. PMC: 5425736. DOI: 10.1007/s12551-015-0186-2. View

13.

Shimura T, Noma N, Sano Y, Ochiai Y, Oikawa T, Fukumoto M . AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother Oncol. 2014; 112(2):302-7. DOI: 10.1016/j.radonc.2014.07.015. View

14.

Bola B, Chadwick A, Michopoulos F, Blount K, Telfer B, Williams K . Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014; 13(12):2805-16. PMC: 4258406. DOI: 10.1158/1535-7163.MCT-13-1091. View

15.

MILLAR D, SCHWERT G . LACTIC DEHYDROGENASE. IX. EFFECT OF PHOTO-OXIDATION UPON ACTIVITY AND COMPLEX FORMATION. J Biol Chem. 1963; 238:3249-55. View

16.

Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y . Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Cancer Immunol Res. 2020; 8(11):1440-1451. DOI: 10.1158/2326-6066.CIR-20-0111. View

17.

Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L . Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008; 452(2):139-46. DOI: 10.1007/s00428-007-0558-5. View

18.

Fu J, Jiang H, Wu C, Jiang Y, Xiao L, Tian Y . Overcoming cetuximab resistance in Ewing's sarcoma by inhibiting lactate dehydrogenase-A. Mol Med Rep. 2016; 14(1):995-1001. DOI: 10.3892/mmr.2016.5290. View

19.

Rogatzki M, Ferguson B, Goodwin M, Gladden L . Lactate is always the end product of glycolysis. Front Neurosci. 2015; 9:22. PMC: 4343186. DOI: 10.3389/fnins.2015.00022. View

20.

de la Cruz-Lopez K, Castro-Munoz L, Reyes-Hernandez D, Garcia-Carranca A, Manzo-Merino J . Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol. 2019; 9:1143. PMC: 6839026. DOI: 10.3389/fonc.2019.01143. View